DE69927400T2 - Pge synthase und verfahren und mitteln zur modulation deren aktivität - Google Patents

Pge synthase und verfahren und mitteln zur modulation deren aktivität Download PDF

Info

Publication number
DE69927400T2
DE69927400T2 DE69927400T DE69927400T DE69927400T2 DE 69927400 T2 DE69927400 T2 DE 69927400T2 DE 69927400 T DE69927400 T DE 69927400T DE 69927400 T DE69927400 T DE 69927400T DE 69927400 T2 DE69927400 T2 DE 69927400T2
Authority
DE
Germany
Prior art keywords
polypeptide
pge
pge synthase
seq
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69927400T
Other languages
German (de)
English (en)
Other versions
DE69927400D1 (de
Inventor
Per-Johan Jakobsson
Bengt Samuelsson
Ralf Morgenstern
Anthony Ford-Hutchinson
Joseph Mancini
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Karolinska Innovations AB
Original Assignee
Karolinska Innovations AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Karolinska Innovations AB filed Critical Karolinska Innovations AB
Publication of DE69927400D1 publication Critical patent/DE69927400D1/de
Application granted granted Critical
Publication of DE69927400T2 publication Critical patent/DE69927400T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/551—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being inorganic
    • G01N33/553—Metal or metal coated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/90—Isomerases (5.)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Inorganic Chemistry (AREA)
  • Pathology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Rheumatology (AREA)
  • Food Science & Technology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Physical Education & Sports Medicine (AREA)
DE69927400T 1998-11-09 1999-11-02 Pge synthase und verfahren und mitteln zur modulation deren aktivität Expired - Lifetime DE69927400T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10768798P 1998-11-09 1998-11-09
US107687P 1998-11-09
PCT/EP1999/008363 WO2000028022A1 (en) 1998-11-09 1999-11-02 Pge synthase and methods and means for modulating its activity

Publications (2)

Publication Number Publication Date
DE69927400D1 DE69927400D1 (de) 2006-02-02
DE69927400T2 true DE69927400T2 (de) 2006-06-29

Family

ID=22317930

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69927400T Expired - Lifetime DE69927400T2 (de) 1998-11-09 1999-11-02 Pge synthase und verfahren und mitteln zur modulation deren aktivität

Country Status (9)

Country Link
US (4) US6395502B1 (https=)
EP (1) EP1129188B1 (https=)
JP (2) JP4503849B2 (https=)
AT (1) ATE305040T1 (https=)
AU (1) AU770307B2 (https=)
CA (1) CA2349529C (https=)
DE (1) DE69927400T2 (https=)
ES (1) ES2249042T3 (https=)
WO (1) WO2000028022A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000028022A1 (en) * 1998-11-09 2000-05-18 Karolinska Innovations Ab Pge synthase and methods and means for modulating its activity
US7169580B1 (en) 2000-02-03 2007-01-30 Chugai Seiyaku Kabushiki Kaisha Protein having PGE2 synthase activity and use thereof
AU2002323358A1 (en) * 2001-08-24 2003-03-10 Karoliska Innovations Ab Methods for preparing purified prostaglandin e synthase
JP2005510220A (ja) * 2001-11-30 2005-04-21 ファイザー・プロダクツ・インク プロスタグランジンｅ合成酵素２遺伝子の破壊
JP2006500066A (ja) * 2002-09-25 2006-01-05 ファルマシア・コーポレーション ミクロソームのプロスタグランジンｅ２シンターゼ発現のアンチセンス調節
WO2004067766A1 (en) * 2003-01-27 2004-08-12 Pfizer Products Inc. Novel methods involving the determination of activity of enzymes that use or produce prostaglandin endoperoxide h2
WO2005024059A2 (en) * 2003-09-09 2005-03-17 Karolinska Innovations Ab Methods for identifying compounds for inhibiting fever
US7638331B2 (en) 2004-01-02 2009-12-29 The Administration of the Tulane Rducation Fund Directed apoptosis in COX-2 overexpressing cancer cells through expression targeted gene delivery
US20090088400A1 (en) * 2007-09-11 2009-04-02 Puymirat Jack Prostaglandin e2 modulation and uses thereof
CN117323320B (zh) * 2023-11-20 2025-10-31 复旦大学附属中山医院 长链脂肪酸12-hht在睡眠呼吸暂停合并高血压中的应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US914356A (en) * 1901-11-30 1909-03-02 Harry Ward Leonard Electric-circuit controller.
AU750187B2 (en) * 1997-09-17 2002-07-11 Johns Hopkins University, The P53-induced apoptosis
WO2000028022A1 (en) * 1998-11-09 2000-05-18 Karolinska Innovations Ab Pge synthase and methods and means for modulating its activity

Also Published As

Publication number Publication date
US20050118696A1 (en) 2005-06-02
US20080153107A1 (en) 2008-06-26
JP2002539762A (ja) 2002-11-26
EP1129188A1 (en) 2001-09-05
CA2349529C (en) 2009-10-27
US20030064493A1 (en) 2003-04-03
AU770307B2 (en) 2004-02-19
US6395502B1 (en) 2002-05-28
EP1129188B1 (en) 2005-09-21
ATE305040T1 (de) 2005-10-15
JP2010115205A (ja) 2010-05-27
CA2349529A1 (en) 2000-05-18
WO2000028022A1 (en) 2000-05-18
US7645601B2 (en) 2010-01-12
DE69927400D1 (de) 2006-02-02
JP4503849B2 (ja) 2010-07-14
ES2249042T3 (es) 2006-03-16
US7192733B2 (en) 2007-03-20
US7067296B2 (en) 2006-06-27
AU1504100A (en) 2000-05-29

Similar Documents

Publication Publication Date Title
Yang et al. The role of voltage-gated calcium channels in pancreatic β-cell physiology and pathophysiology
DE68928043T2 (de) Interleukin-4-Rezeptoren
DE69533923T2 (de) Cytokinin-designiertes lerk-5
DE69427392T2 (de) Acethylhydrolase des plättchen aktivierenden faktors
DE69434670T2 (de) Verfahren und produkt für die regulation des reaktionsvermögens von zellen auf äussere signale
DE69535274T2 (de) Verwendung eines menschlichen interleukin-11 rezeptors
DE69927400T2 (de) Pge synthase und verfahren und mitteln zur modulation deren aktivität
DE602004008658T2 (de) Behandlung neurodegenerativer krankheiten
JP2009132715A (ja) 新規クラスｉｉサイトカイン受容体およびその使用
DE69934903T2 (de) Mitogene regulatoren
DE69737633T2 (de) ZU FIBROBLASTEN-WACHSTUMSFAKTOR HOMOLOGE FAKTOREN (FHFs) UND VERFAHREN DER ANWENDUNG
DE69935414T2 (de) Humanes h-TRCP Protein
DE69734586T2 (de) Retinoid-metabolisierendes protein
DE69535316T2 (de) Als lerk6 bezeichnetes cytokin
US6296848B1 (en) GRB2 associating polypeptides and nucleic acids encoding therefor
DE69931345T2 (de) Gen, welches für neues transmembranprotein kodiert
DE69530261T3 (de) Durch Zelldichte stimulierte Protein-Tyrosin-Phosphatasen
JP2003523723A (ja) ヘルマンスキー−パドラック症候群タンパク質相互作用タンパク質およびその使用の方法
DE19617940A1 (de) Nebenhoden-spezifisches Rezeptorprotein und dessen Verwendung
CA2477969A1 (en) Falp proteins
DE60105609T2 (de) Metabolismuskontrolle mittels zusamensetzungen des humanen 2-oxoglutarat-trägers
EP1436327B1 (de) Ee3-proteinfamilie und zugrundeliegende dna-sequenzen
JPH08508397A (ja) 新規なレセプター型ホスホチロシンホスファターゼ‐ベータ
DE60226277T2 (de) Cytotoxisches protein und dessen verwendung
DE69937644T2 (de) Ucp4

Legal Events

Date Code Title Description
8364 No opposition during term of opposition